Opinion

Video

Key Takeaways on the Evolving NMIBC Treatment Landscape

Author(s):

Gordon A. Brown, DO,Siamak Daneshmand, MD

The panel concludes by offering key takeaways on the evolving treatment landscape for BCG-unresponsive non–muscle invasive bladder cancer.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Related Videos
      Doctor consulting patient | Image Credit: © Liudmila Dutko - stock.adobe.com
      Strategies to bridge gender disparities in AAS and citations in the oncology literature
      4 experts in this video
      Case 3: A 49-Year-Old Man With Recurrent Non–Muscle-Invasive Bladder Cancer
      4 experts in this video
      Case 2: A 68-Year-Old Woman With Non–Muscle-Invasive Bladder Cancer
      Female doctor typing on her laptop computer in medical office | Image Credit: © Rostislav Sedlacek - stock.adobe.com
      Study findings highlight gender gaps in oncology authorship and citation
      4 experts in this video
      Case 1: A 79-Year-Old Man With Non–Muscle-Invasive Bladder Cancer
      4 experts in this video
      Non–Muscle Invasive-Bladder Cancer Overview
      Laura Davis, MD, on link between microplastics and bladder cancer
      Laura Davis, MD, on link between microplastics and bladder cancer
      Rebecca A. Campbell, MD, answers a question during a Zoom video interview
      Rebecca A. Campbell, MD, discusses citation rates for men and women in the oncology literature
      Sam Chang, MD, shares updated data on nogapendekin alfa inbakicept in NMIBC
      Sam Chang, MD, shares updated data on nogapendekin alfa inbakicept in NMIBC
      Joshua J. Meeks, MD, PhD, gives an answer during a Zoom video interview
      Expert discusses the NMIBC trials landscape
      Related Content
      FDA approves mitomycin intravesical solution for recurrent LG-IR-NMIBC
      June 12th 2025

      FDA approves mitomycin intravesical solution for recurrent LG-IR-NMIBC

      Hannah Clarke
      The approval is supported by findings from the phase 3 ENVISION trial.
      medical depiction of bladder cancer
      May 31st 2023

      Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

      Urology Times staff
      In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
      Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
      June 9th 2025

      En bloc resection of bladder tumor: Is it the way forward?

      Jeremy Teoh, MBBS, FRCSEd (Urol), FCSHK, FHKAM (Surgery)
      "As urologists, we are the gatekeepers, and we must always perform the best possible surgery to optimize oncological outcomes," writes Jeremy Teoh, MBBS, FRCSEd (Urol), FCSHK, FHKAM (Surgery).
      Dr. Lutz on sexual dysfunction, performance anxiety, and Peyronie's disease
      May 26th 2022

      Dr. Lutz on sexual dysfunction, performance anxiety, and Peyronie's disease

      Urology Times staff
      “We know that erectile dysfunction is really an important issue that can be a harbinger for other underlying cardiovascular or neurological health issues,” says Michael Lutz, MD.
      FDA updates in urology: May 2025
      June 2nd 2025

      FDA updates in urology: May 2025

      Hannah Clarke
      A recap of the FDA submissions and regulatory decisions in urology from May 2025.
      Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
      June 1st 2025

      NIAGARA: ctDNA analysis highlights durvalumab’s impact in MIBC

      Benjamin P. Saylor
      The findings also lend further credence to the muscle-invasive bladder cancer treatment regimen, investigators reported.
      © 2025 MJH Life Sciences

      All rights reserved.